| 刘和俊,李乾兵,姚克晗,徐裕丰,童亚玲,李 文.噻托溴铵联合奥达特罗治疗慢性阻塞性肺疾病患者的疗效及对免疫功能的影响[J].,2020,(14):2728-2731 |
| 噻托溴铵联合奥达特罗治疗慢性阻塞性肺疾病患者的疗效及对免疫功能的影响 |
| The Effect of Tiotropium Bromide Combined with Olodaterol in the Treatment of COPD in Stable Stage and Its Influence on Immune Function |
| 投稿时间：2020-02-04 修订日期：2020-02-28 |
| DOI：10.13241/j.cnki.pmb.2020.14.028 |
| 中文关键词: 噻托溴铵 奥达特罗 慢性阻塞性肺疾病 疗效 免疫功能 |
| 英文关键词: Tiotropium bromide Olodaterol Chronic obstructive pulmonary disease Efficacy Immune function |
| 基金项目:广东省医学科学技术研究基金项目(B20161465)；广东医科大学校院联合科研基金（L2016025） |
|
| 摘要点击次数: 618 |
| 全文下载次数: 289 |
| 中文摘要: |
| 摘要 目的：探讨噻托溴铵联合奥达特罗治疗慢性阻塞性肺疾病（COPD）患者的疗效及对免疫功能的影响。方法：选取我院于2018年10月到2019年10月期间接收的108例COPD患者，按照随机数字表法将患者分为噻托溴铵组（n=36，噻托溴铵治疗）、奥达特罗组（n=36，奥达特罗治疗）、联合组（n=36，噻托溴铵联合奥达特罗治疗），比较三组患者疗效、肺功能、免疫功能及不良反应。结果：联合组治疗3个月后的临床总有效率、肺活量（FVC）、第1秒用力呼气容积（FEV1）、FEV1/FVC、CD3+、CD4+、免疫球蛋白G（IgG）、免疫球蛋白M（IgM）均高于奥达特罗组、噻托溴铵组（P<0.05）。奥达特罗组、噻托溴铵组治疗3个月后的的临床总有效率、FVC、FEV1、FEV1/FVC、CD3+、CD4+、IgG、IgM比较差异无统计学意义（P>0.05）。三组治疗期间不良反应发生率整体比较差异无统计学意义（P>0.05）。结论：噻托溴铵联合奥达特罗治疗COPD患者，疗效显著，可有效改善免疫功能及肺功能，且不增加不良反应发生率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of tiotropium bromide combined with olodaterol in the treatment of chronic obstructive pulmonary disease (COPD) and its influence on immune function. Methods: From October 2018 to October 2019, 108 patients with COPD were selected, they were randomly divided into tiotropium group (n=36, tiotropium bromide treatment), olodaterol group (n=36, olodaterol treatment), combined group (n=36, tiotropium bromide combined with olodaterol treatment). The efficacy, lung function, immune function and adverse reactions of the three groups were compared. Results: The clinical total effective rate, Vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC, CD3+, CD4+, immunoglobulin G (IgG), immunoglobulin M (IgM) of the combined group after 3 months of treatment were all higher than those of the olodaterol group and tiotropium group (P<0.05). There were no significant differences in the total clinical effective rate, FVC, FEV1, FEV1/FVC, CD3+, CD4+, IgG and IgM between the olodaterol group and tiotropium group (P>0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the three groups during treatment (P>0.05). Conclusion: Tiotropium bromide combined with olodaterol in the treatment of patients with COPD, the effect is significant, which can effectively improve the immune function and lung function, and does not increase the incidence of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
